AnaBios generates highly valuable, predictive human data before clinical trials, ensuring the selection of the most effective and safest drugs, thereby reducing the time and expense related to clinical trial failures. Through its proprietary technology, based on the use of human donor organs and tissues, AnaBios studies ex-vivo human responses to drugs and further investigates the molecular and functional basis of relevant human physiology. AnaBios's research focuses primarily on the areas of high, unmet medical need, including cardiac disease and safety, pain, PKD kidney disease, and neurodegeneration. AnaBios markets its products and services directly and through distributors and partners worldwide. AnaBios also drives an internal drug discovery platform via in-licensed programs from partners in the pharmaceutical industry and academia.

🔗 http://anabios.com

CONNECT:

Paul Miller, Chief Corporate Development
📧 pmiller@anabios.com
📞 858.366.8608
3030 Bunker Hill Street, Suite 312
San Diego, CA 92109